Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) hit a new 52-week low during trading on Tuesday . The stock traded as low as C$0.05 and last traded at C$0.06, with a volume of 5071 shares traded. The stock had previously closed at C$0.06.
Hemostemix Stock Performance
The company has a market cap of C$9.89 million, a PE ratio of -2.50 and a beta of 0.18. The stock’s 50 day simple moving average is C$0.06 and its two-hundred day simple moving average is C$0.08. The company has a quick ratio of 0.48, a current ratio of 0.24 and a debt-to-equity ratio of -66.09.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Read More
- Five stocks we like better than Hemostemix
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
